Home/Pipeline/Protease Inhibitor Discovery Programs

Protease Inhibitor Discovery Programs

Oncology (Undisclosed)

DiscoveryActive

Key Facts

Indication

Oncology (Undisclosed)

Phase

Discovery

Status

Active

Company

Medivir

About Medivir

Medivir is a publicly traded, clinical-stage oncology company with a legacy in antiviral drug discovery, most notably contributing to the hepatitis C therapy simeprevir. The company has successfully pivoted to focus exclusively on cancer, applying its proprietary platforms to develop novel therapies for hard-to-treat tumors. Its strategy centers on advancing its lead asset, fostroxacitabine bralpamide, in liver cancer while expanding its pipeline through targeted discovery and partnerships. Medivir's mission is to deliver innovative treatments where current options are limited or non-existent.

View full company profile

Therapeutic Areas

Oncology Liver Cancer

Other Oncology (Undisclosed) Drugs

Drug	Company	Phase	Status
CLD-601	Calidi Biotherapeutics	Discovery	Active
Nucleoside/Nucleotide Discovery Programs	Medivir	Discovery	Active
Orion Collaboration Program 1	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 2	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 3	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 4-6 (Extended)	Glykos Finland	Research	Active
ISB 830	Glenmark Pharmaceuticals	Preclinical	Active
TEM-1	Tempus AI	Discovery/Preclinical	Active
TEM-2	Tempus AI	Discovery/Preclinical	Active
TEM-3	Tempus AI	Discovery/Preclinical	Active
TEM-4	Tempus AI	Discovery/Preclinical	Active
TEM-5	Tempus AI	Discovery/Preclinical	Active